kan-101
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 21, 2020 (NCT04248855)
Timeline
Indications
Studied for
Mechanism of action
- Unspecified targetImmunity, desensitized
immunity, desensitized
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06001177 | Phase 2 | Dec 13, 2023 | Anokion SA, Kanyos Bio, Inc., Pfizer |
| NCT05574010 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2022 | Anokion SA, Kanyos Bio, Inc., Pfizer |
| NCT04248855 | Phase 1 | Jan 21, 2020 | Kanyos Bio, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kanyos Bio, Inc. | For profit | 3 | 3 | 2 | 2020 |
| Anokion SA | For profit | 2 | 0 | 1 | 2022 |
| Pfizer | For profit | 2 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1